08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Amikacin Fosfomycin Inhalation System regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to Amikacin Fosfomycin Inhalation System for adjunctive treatment of mechanically ventilated patients with bacterial pneumonia. The product is now eligible for an additional 5 years of market...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Amikacin Fosfomycin Inhalation System: Phase II started

Cardeas began the double-blind, placebo-controlled, international Phase II IASIS trial to evaluate Amikacin Fosfomycin Inhalation System delivered twice daily using the eFlow Inline Nebulizer System from Pari GmbH (Starnberg, Germany) for 10 days in...